Caladrius is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular and autoimmune disease, among other areas. Our current product candidates include three developmental treatments for cardiovascular diseases based on our CD34+ cell therapy platform: CLBS12, recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe, eligible for early conditional approval for the treatment of critical limb ischemia in Japan based on an ongoing clinical trial; CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial in the U.S.A. for the treatment of coronary microvascular dysfunction; and CLBS14, a Phase 3 ready clinical program in no option refractory disabling angina and recipient of a RMAT designation in the U.S.A.

**INVESTMENT HIGHLIGHTS**

- **CD34+ cell therapy platform company with an advanced clinical pipeline with two programs with cell therapy “breakthrough” designation**
- Proprietary field-leading technology in multi-billion dollar global indications backed by a strong IP portfolio
- Multiple potential value creating events in the next 12 months based on development milestones across the pipeline
- Seasoned management team with noteworthy domain expertise along with big pharma and emerging biotech experience
- Strong balance sheet; $29.2 million in cash (September 30, 2019) with no debt and cash runway projected through 1Q 2021

**C-SUITE LEADERSHIP TEAM**

- **David Mazzo, PhD**
  - President
  - Chief Executive Officer
- **Douglas Losordo, MD**
  - Executive Vice President
  - Global Head of R&D
  - Chief Medical Officer
- **Joseph Talamo, CPA, MBA**
  - Senior Vice President
  - Chief Financial Officer

**MARKET SNAPSHOT**

- **Ticker Symbol**: CLBS
- **Exchange**: NASDAQ
- **52-Week Price Range**: $2.00 - $5.44
- **Shares Outstanding (9/30)**: 10.4 million
- **Cash & Investments (9/30)**: $29.2 million
- **Fiscal Year-End**: December 31

**POTENTIAL VALUE CREATING MILESTONES**

- **1Q 2020**: Complete Phase 2 enrollment in CLBS12
- **1Q 2020**: Announce ESCaPE-CMD study topline data
- **YE 2020**: Announce Phase 2 CLBS12 topline data
CD34+ CELL THERAPY PLATFORM

- Naturally occurring vascular repair (endothelial progenitor) cell
- Provokes restorative angiogenesis of the microvasculature
- CD34+ cells re-establish blood flow to under-perfused tissues
- CD34 is a cell surface protein that identifies a subset of mononuclear cells in the bone marrow and circulation
- CD34+ cells are pre-programmed vascular repair cells that promote angiogenesis of the microvasculature. Caladrius’ proprietary platform technology selects and delivers a potent, concentrated population of the patient’s own CD34+ cells for optimal therapeutic benefit.

CD34+ CELL THERAPY PIPELINE

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>Development Stage</th>
<th>Commercialization Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLBS12</td>
<td>CLI</td>
<td>Registration eligible Phase 2 <em>(Japan; ongoing)</em></td>
<td>2021</td>
</tr>
<tr>
<td>CLBS16</td>
<td>CMD</td>
<td>Proof-of-concept <em>(USA; ongoing)</em></td>
<td>TBD</td>
</tr>
<tr>
<td>CLBS14</td>
<td>NORDA</td>
<td>Phase 3 confirmatory <em>(USA; pending funding)</em></td>
<td>TBD</td>
</tr>
</tbody>
</table>

- GCSF mobilization eliminates need for surgical bone marrow aspiration
- No genetic manipulation or expansion of cells
- Four days or less from donation to treatment
- Cost-of-goods an order of magnitude less expensive than CAR-T therapies